Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the companies still plan to file the vaccine with regulators.
- Home |
- Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
- March 23, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
